title: Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma.
abstract: Autoantibodies against tumor-associated antigens (TAAs) such as insulin-like growth factor II mRNA-binding proteins (IMPs), p53, c-myc, and survivin were analyzed in patients with hepatocellular carcinoma (HCC), using recombinant proteins of these antigens. Eight of 86 (9.3%) HCC patients had one or more of these autoantibodies. However, serum alpha-fetoprotein (AFP) levels ranged within normal limits in HCC patients with anti-TAAs except for one case with anti-IMP1. One of the HCC patients had autoantibodies against IMP1, IMP3 and p53 before the diagnosis of HCC. These findings may indicate that anti-TAAs seem to be supplementary serological markers for the diagnosis of HCC in AFP-negative cases and that autoantibodies against IMP1, IMP3 and p53 are candidates for predictive markers of HCC development.
authors.affiliation: W.M. Keck Autoimmune Disease Center, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
authors.forename: Takashi
authors.initials: T
authors.lastname: Himoto
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kuriyama
authors.forename: Jian-Ying
authors.initials: JY
authors.lastname: Zhang
authors.forename: Edward K L
authors.initials: EK
authors.lastname: Chan
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Kimura
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Masaki
authors.forename: Naohito
authors.initials: N
authors.lastname: Uchida
authors.forename: Mikio
authors.initials: M
authors.lastname: Nishioka
authors.forename: Eng M
authors.initials: EM
authors.lastname: Tan
mesh_terms: D000951:Antigens, Neoplasm / Q000737:chemistry*; D001323:Autoantibodies / Q000737:chemistry*; D014408:Biomarkers, Tumor / Q000378:metabolism; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000378:metabolism*; D018076:DNA, Complementary / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005355:Fibrosis; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008099:Liver / Q000378:metabolism; D008113:Liver Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry; D000077022:Survivin; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D000509:alpha-Fetoproteins / Q000096:biosynthesis
chemical_list: D000951:Antigens, Neoplasm; D001323:Autoantibodies; C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D018076:DNA, Complementary; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D011994:Recombinant Proteins; D000077022:Survivin; D016159:Tumor Suppressor Protein p53; D000509:alpha-Fetoproteins